| A | B | |
|---|---|---|
| 1 | Main | |
| 2 | Viread (tenofovir) for Hepatitis B | |
| 3 | Enrollment in Phase II trials complete - 102 and 103 - Viread or Hepsera randomized over 48 weeks - data in 2h07 |
| A | B | |
|---|---|---|
| 1 | Main | |
| 2 | Viread (tenofovir) for Hepatitis B | |
| 3 | Enrollment in Phase II trials complete - 102 and 103 - Viread or Hepsera randomized over 48 weeks - data in 2h07 |
Martin Shkreli